News
Archive
Vascular Therapies completes $25 million private financing
Paragraf raises $60 million in Series B financing
NorthSea Therapeutics initiates Phase I trial of SEFA-6179, targeting the orphan indication intestinal failure-associated liver disease
NorthSea Therapeutics completes $80 million Series C fundraising to advance clinical programs in metabolic disorders
Icosabutate latest phase 2b interim data show significant decreases in NASH and fibrosis biomarkers independent of fibrosis stage and disease severity
Cambridge Epigenetix raises $88 million Series D financing to advance best-in-class DNA sequencing technology platform
Back To News

May 11, 2021
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.